Pfizer (PFE) stock prices updated...
 

Pfizer stock price

Pfizer latest news:


  • 12/12/2017 14:59:08

    BRIEF-U.S. FDA Extends Action Date For Expanded Label of Pfizer's Xeljanz In Ulcerative Colitis By Three Months

    Pfizer Inc(PFE): * U.S. FOOD AND DRUG ADMINISTRATION EXTENDS ACTION DATE FOR XELJANZ® SUPPLEMENTAL NEW DRUG APPLICATION IN ULCERATIVE COLITIS BY THREE MONTHS. * Pfizer Inc (PFE) - FDA HAS PROVIDED AN ANTICIPATED PRESCRIPTION DRUG USER FEE ACT DATE IN JUNE 2018.

  • 12/06/2017 15:16:19

    Gene-therapy approach to hemophilia finds success in study, Spark stock surges

    Spark Therapeutics Inc. stock surged Wednesday afternoon after the company announced positive results from a study of a gene-therapy approach to hemophilia. The drug, developed and tested in a collaboration with Pfizer Inc. , involves a single injection meant to help those suffering from hemophilia B, a disease that keep blood from clotting and is typically treated with regular and costly infusions. The study followed 10 adult males for 492 weeks and found that the number of episodes of bleeding decreased from an average of 11.1 a year before administration to 0.4 per year after, while infusions were reduced by 99%. The results were published in The New England Journal of Medicine on Wednesday, the companies said in a news release. Spark shares jumped as much as 9% in late trading after the announcement Wednesday, while Pfizer shares were unchanged.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/06/2017 09:32:30

    Viagra goes generic: Pfizer to launch own little white pill

    Pfizer launching own generic Viagra as other cheap versions are headed to US market

  • 12/04/2017 09:11:16

    BRIEF-Acentrus Specialty Signs New Agreement With Pfizer Oncology

    Pfizer Inc(PFE): * ACENTRUS SPECIALTY SIGNS NEW AGREEMENT WITH PFIZER ONCOLOGY. * ACENTRUS SPECIALTY SAYS SIGNED NEW AGREEMENT THAT OFFERS QUALIFIED ACENTRUS HOSPITAL AND HEALTH SYSTEM CLIENTS ACCESS TO PFIZER ONCOLOGY PRODUCTS. * ACENTRUS SPECIALTY - CONTRACT INCLUDES 5 ORAL ONCOLYTIC PRODUCTS; IBRANCE, BOSULIF, SUTENT, INLYTA AND XALKORI​ Source text for Eikon: Further company coverage:

  • 12/01/2017 09:23:56

    Cancer Space Update: Pfizer's Bavencio Fails in Phase III

    There was no major news in the cancer space this week except the failure of Pfizer Inc s PFE Bavencio in a gastric cancer study In a setback to Eisai Co Ltd ESALY National Institute of Health and Care Excellence NICE did not recommend the approval of its breast cancer drug

  • 11/30/2017 23:25:36

    BRIEF-Pfizer Says Entered Into Agreement To Develop And Commercialize Cresemba In China And Asia Pacific

    Pfizer Inc(PFE): * SAYS ‍PFIZER ENTERS INTO AGREEMENT TO DEVELOP AND COMMERCIALIZE CRESEMBA IN CHINA AND ASIA PACIFIC REGION​ Source text for Eikon: Further company coverage:

  • 11/30/2017 23:20:33

    BRIEF-Basilea Extends Existing License Agreement With Pfizer For Cresemba

    BASILEA PHARMACEUTICA AG: * BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER FOR ANTIFUNGAL CRESEMBA® TO CHINA AND ASIA PACIFIC. * BASILEA UPDATES ITS FINANCIAL GUIDANCE FOR 2017 - IMPROVED RESULT EXPECTED. * ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO USD 226 MILLION AND MID-TEEN ROYALTIES ON SALES. * WILL RECEIVE UPFRONT PAYMENT OF USD 3 MILLION.

  • 11/30/2017 00:41:47

    BRIEF-Glaxosmithkline says ViiV Healthcare starts Phase 3 HIV prevention study in women

    * ‍VIIV HEALTHCARE, CO OWNED BY GSK, WITH PFIZER INC. AND SHIONOGI LTD AS SHAREHOLDERS, TO START PHASE III STUDY FOR PREVENTION OF HIV INFECTION IN SEXUALLY ACTIVE WOMEN​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

  • 11/28/2017 09:01:53

    UPDATE 1-UK gives Pfizer world's first over-the-counter Viagra approval

    LONDON, Nov 28 (Reuters) - Pfizer's big-selling erectile dysfunction drug Viagra has been given a green light for sale without a prescription in Britain, the first country to grant it over-the-counter status.

  • 11/28/2017 06:16:56

    BRIEF-Zhejiang Hisun Pharmaceutical's share trade to resume after Pfizer exited China JV

    Zhejiang Hisun Pharmaceutical Co Ltd : * SAYS SHARE TRADE TO RESUME ON NOV 29 AFTER PFIZER EXITED CHINA JOINT VENTURE WITH THE COMPANY Source text in Chinese: http://bit.ly/2iZ534b Further company coverage:

  • 11/28/2017 06:05:26

    BRIEF-Merck And Pfizer Provide Update On Phase III Javelin Gastric 300 Study In Patients With Pre-Treated Advanced ...

    Pfizer Inc(PFE): * MERCK AND PFIZER PROVIDE UPDATE ON PHASE III JAVELIN GASTRIC 300 STUDY IN PATIENTS WITH PRE-TREATED ADVANCED GASTRIC CANCER.

  • 11/21/2017 12:25:13

    ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance

    ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, said on Tuesday that the Food and Drug Administration has approved its two-drug HIV regimen. The therapy, Juluca, is the first such HIV drug composed of just two drugs -- dolutegravir and rilpivirine, both of which have been previously approved -- while other HIV regimens are typically composed of at least three drugs. This advancement could make the regimen more tolerable for the patient, according to Dr. Debra Birnkrant, director of the Division of Antiviral Products in the FDA's Center for Drug Evaluation and Research. Juluca is approved for individuals with HIV-1 who have been stable on a regimen for at least half a year, have no history of treatment failure and no known resistance to Juluca's individual components, ViiV said. GlaxoSmithKline shares declined 0.8% in Tuesday trade; shares have dropped nearly 10% over the last three months, compared with a 7% rise in the S&P 500 and a nearly 8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/16/2017 13:47:47

    U.S. FDA expands approval for Pfizer cancer drug Sutent

    The U.S. Food and Drug Administration on Thursday approved the use of Pfizer Inc's (PFE) cancer drug Sutent to help prevent kidney cancer from returning following surgical removal of a kidney. Sutent was approved in 2006 for patients with gastrointestinal stromal tumors and advanced kidney cancer.

  • 11/13/2017 09:56:39

    UPDATE 1-Pfizer creates chief operating officer role for Bourla

    NEW YORK, Nov 13 (Reuters) - Drugmaker Pfizer Inc has promoted Albert Bourla to the newly created post of chief operating officer, freeing up Chief Executive Officer Ian Read to focus more on long-term strategy and engaging with government and industry leaders.

  • 11/09/2017 07:25:29

    Dow futures fall as 26 of 30 components trade lower premarket

    As the Dow Jones Industrial Average threatens to open with a triple-digit loss, 26 of the 30 components traded lower in premarket trade. Among the biggest decliners, shares of Intel Corp. fell 1.3%, American Express Co. shed 1% and Cisco Systems Inc. fell 0.7%. Among the gainers, shares of both Boeing Co. and Pfizer Inc. edged up 0.3%. Dow futures slumped 92 points ahead of the open.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/31/2017 12:06:45

    Pfizer expects broad interest for consumer health business

    NEW YORK (Reuters) - Pfizer Inc, the largest U.S. drugmaker, expects no shortage of suitors for its consumer health business and said it would decide whether to sell, spin off or retain the unit next year.

  • 10/31/2017 09:55:03

    Pfizer beats 3Q net forecasts on lower charges, higher sales

    Pfizer doubles 3Q net income due to slightly higher sales and lower charges, tops profit expectations

  • 10/31/2017 08:16:16

    Pfizer Earnings Not Enough for Investors


  • 10/26/2017 01:39:40

    Pfizer sets date for auction of consumer healthcare unit: Reuters

    Pfizer Inc. will begin the auction process for its consumer healthcare unit in November, which it hopes will end in a $15 billion sale, Reuters reported late Wednesday, citing sources close to the matter. GlaxoSmithKline PLC. and Reckitt Benckiser are among those companies that have said they would consider bidding for the Pfizer unit. One of the sources told Reuters that initial discussions with Reckitt have already happened. Other possible bidders may include Procter & Gamble , Sanofi SA , Johnson & Johnson and Nestle [s: ch:nesn], sources said. The companies have been contacted for comment.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/25/2017 23:16:39

    UK Stocks-Factors to watch on Oct 26

    Oct 26 (Reuters) - Britain's FTSE 100 index is seen opening up 16 points at 7,463.5 on Thursday, according to financial bookmakers. * GLAXOSMITHKLINE: The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck & Co's established product Zostavax. * GSK/RB: Pfizer to kick off auction process for its consumer healthcare business in November, paving the way for a potentia

  • 10/25/2017 12:35:33

    Exclusive: Pfizer to launch consumer health sale in November - sources

    Pfizer plans to kick off an auction process for its consumer healthcare business in November, paving the way for a potential $15 billion-plus sale of the headache pill to lip balm business, sources close to the matter told Reuters.

  • 10/25/2017 10:54:34

    GlaxoSmithKline stock plummets 6% after concerns about dividend risk

    GlaxoSmithKline PLC shares plummeted 6% in extremely heavy midday trade Wednesday on concerns that the company's interest in Pfizer Inc.'s over-the-counter business could put its dividend at risk. After being asked if she could give investors assurances that the potential deal would carry no dividend risk, Chief Executive Emma Walmsley did not exactly give those assurances. "We know the dividend matters to our investors. We intend and we do pay it now as a function of our free cash flow after investing in the necessary priorities to secure long-term growth for the company," Walmsley said, according to the FactSet transcript of the company's third-quarter earnings call, adding, "we confirmed our intentions to pay the dividend in 2017 of 80 pence and again in 2018 and then we will be returning to declaring the dividend quarterly and not giving a more specific outlook beyond that." When Walmsley was again pressed about the potential Pfizer deal, she said it was "too premature and hypothetical." "For us, even though we believe pricing (mostly in Respiratory) and competitive concerns (Respiratory and HIV) are largely factored into the stock at current levels, investors remain focused on the safety of the dividend," said Leerink Partners analyst Seamus Fernandez. GlaxoSmithKline shares have dropped 9.5% over the last three months, compared with a 2.9% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/10/2017 14:15:27

    Pfizer considers consumer business sale

    Pfizer to sell consumer business

  • 10/10/2017 14:14:16

    Pfizer considers consumer business sale

    Pfizer may be done selling ChapStick, Advil, Robitussin and other brands that people can buy without a prescription.

  • 10/10/2017 11:04:06

    Pfizer weighs $15 billion sale of consumer healthcare business

    (Reuters) - Pfizer said on Tuesday it was considering the sale or spin-off of its consumer healthcare business, shaking up the industry and potentially putting a headache pill to lip balm operation worth some $15 billion up for grabs.

  • 10/10/2017 11:01:33

    UPDATE 4-Pfizer weighs $15 bln sale of consumer healthcare business

    * Possible buyers include existing OTC drugmakers and Nestle (Adds Breakingviews link)

  • 10/10/2017 09:02:42

    Pfizer mulls sale of consumer business

    The company's consumer health business contains brands such as Advil, Robitussin and ChapStick.

  • 10/10/2017 05:27:00

    Pfizer is mulling sale, spin-off of its consumer health-care business

    Pfizer on Tuesday said it is reviewing strategic alternatives for its consumer health-care business.

  • 09/21/2017 15:00:23

    Versartis shares halted

    Shares of Versartis Inc. were halted late Thursday after the biopharmaceutical company said its drug somavaratan failed to meet its primary endpoint in a phase 3 trial. The drug, a form of human growth hormone that seeks to treat growth-hormone deficiency, failed to demonstrate superiority to Genotropin, an offering from Pfizer Inc. , in a study focusing on pediatric growth-hormone deficiency. "We are very surprised and disappointed to learn the outcome," Chief Executive Jay Shepard said in Thursday's announcement, adding that the company planned to provide a corporate update later this year. Versartis shares have gained 27% in the past three months, more than 10 times the gains for the S&P 500 Index in the same period, and nearly 45% so far this year. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/20/2017 13:35:29

    Pfizer accuses Johnson & Johnson of 'anticompetitive practices' in lawsuit

    Pfizer filed a lawsuit against fellow pharmaceutical giant Johnson & Johnson over "anticompetitive practices" with the drug Remicade.        

  • More trends:

    Pharmerica CorporationPMC | PHH CorpPHH | Philip Morris International IncPM | Philippine Long Distance Telephone CompanyPHI | Phillips 66PSX | Phillips 66 Partners LPPSXP | Phoenix CompaniesPFX | Phoenix CompaniesPNX | Phoenix New Media LimitedFENG | Physicians Realty TrustDOC |